Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2024-03-19 Major Shareholding Noti…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (HLB Co., Ltd.) and its special related parties in the issuer (HLB Therapeutics Co., Ltd.). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-03-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in shareholding by major stakeholders, which corresponds to the 'Director's Dealing' category in the provided schema.
2024-03-19 Korean
전환가액의조정 (제15회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) issued by HLB Therapeutics. This type of disclosure, specifically detailing changes to conversion prices and the resulting impact on the number of convertible shares, falls under capital structure changes. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for updates on financing activities and capital structure changes.
2024-03-18 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous disclosure of 'Changes in Sales or Profit/Loss Structure of 30% or more'. It provides updated financial figures (Revenue, Operating Profit, Net Income) due to adjustments made during the external audit process. Since this is an initial announcement of financial results (even if it is a correction of a previous release) and not a full annual report or a transcript, it falls under the Earnings Release category. FY 2023
2024-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from HLB Therapeutics. It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit/loss) for both consolidated and separate financial statements, and details regarding the auditor. While it contains financial data, it is a standard regulatory disclosure announcement of the audit results rather than the full 10-K annual report itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-18 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2023 (Jan 1, 2023 to Dec 31, 2023) filed with the Financial Supervisory Service and Korea Exchange. It contains comprehensive financial statements, business descriptions, management discussions, and corporate governance details. This is the standard Korean regulatory filing equivalent to a 10-K. FY 2023
2024-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.